2022

DALTONbio was awarded the  Specialization, Refinement, Specialty, Innovation "Small Giant Company" by the Ministry of Industry and Information Technology of China

"Specialization, Refinement, Specialty, Innovation" Small and Medium Company in Zhejiang Province

2021

Chinese Academy of Sciences STS Regional Key Project "Development of Tumor Molecular Diagnostic Kits and Testing Instruments"

DALTONbio became the executive vice president of Zhejiang Life and Health Industry Innovation Committee

2020

DALTONbio launches COVID-10 IgM/IgG Rapid Combined Antibody Test (ICA) kit

2019

DALTONbio launches the fully automated HPV detection instrument

"DH5" and "DH6" launch clinical trials

2018

DALTONbio receives marketing approval for dual staining immunocytology products.

2016

DALTONbio launches DH three-year follow-up clinical trial

2014

China Food and Drug Administraton (now NMPA ) issued registration certificates for "DH2" and "DH3" medical devices to DALTONbio

DALTONbio officially launched the Human Papillomavirus (HPV) Nucleic Acid Test Kit and started nationwide sales.

2012

DALTONbio established a postdoctoral fellow R&D station

2011

DALTONbio and Zhejiang University collaborate to establish a joint R&D centre for antibody technology

2010

Hangzhou DALTON BioSciences, Ltd. established

DALTONbio obtained medical device manufacturing license